• David E Griffith, Rachel Thomson, Patrick A Flume, Timothy R Aksamit, Stephen K Field, Doreen J Addrizzo-Harris, Kozo Morimoto, Wouter Hoefsloot, Kevin C Mange, Dayton W Yuen, Monika Ciesielska, Richard J Wallace, Jakko van Ingen, Barbara A Brown-Elliott, Chris Coulter, Kevin L Winthrop, and CONVERT Study Group.
• Pulmonary Infectious Disease Section, The University of Texas Health Science Center at Tyler, Tyler, TX. Electronic address: griffithd@njhealth.org.
• Chest. 2021 Sep 1; 160 (3): 831-842.

BackgroundIn the CONVERT study, treatment with amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) met the primary end point of increased culture conversion by month 6 in patients with treatment-refractory Mycobacterium avium complex lung disease (ALIS plus GBT, 29% [65/224] vs GBT alone, 8.9% [10/112]; P < .0001).Research QuestionIn patients who achieved culture conversion by month 6 in the CONVERT study, was conversion sustained (negative sputum culture results for 12 months with treatment) and durable (negative sputum culture results for 3 months after treatment) and were there any additional safety signals associated with a full treatment course of 12 months after conversion?Study Design And MethodsAdults were randomized 2:1 to receive ALIS plus GBT or GBT alone. Patients achieving culture conversion by month 6 continued therapy for 12 months followed by off-treatment observation.ResultsMore patients randomized to ALIS plus GBT (intention-to-treat population) achieved conversion that was both sustained and durable 3 months after treatment vs patients randomized to GBT alone (ALIS plus GBT, 16.1% [36/224] vs GBT alone, 0% [0/112]; P < .0001). Of the patients who achieved culture conversion by month 6, 55.4% of converters (36/65) in the ALIS plus GBT treated arm vs no converters (0/10) in the GBT alone arm achieved sustained and durable conversion (P = .0017). Relapse rates through 3 months after treatment were 9.2% (6/65) in the ALIS plus GBT arm and 30.0% (3/10) in the GBT alone arm. Common adverse events among ALIS plus GBT-treated patients (dysphonia, cough, dyspnea, hemoptysis) occurred mainly within the first 8 months of treatment.InterpretationIn a refractory population, conversion was sustained and durable in more patients treated with ALIS plus GBT for 12 months after conversion than in those treated with GBT alone. No new safety signals were associated with 12 months of treatment after conversion.Trial RegistryClinicalTrials.gov; No.: NCT02344004; URL: www.clinicaltrials.gov.Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

5 keywords...

hide…